| DEFINIUM THERAPEUTICS |
| Kanada |
| Gesundheit |
| CA24477V1058 / A420P3 |
| MMQ0 (Frankfurt) / DFTX (NASDAQ) |
| FRA:MMQ0, ETR:MMQ0, MMQ0:GR, NASDAQ:DFTX |
| - |
| https://definiumtx.com/ |
|
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses..
>Volltext.. |
| 1968.74 Mio. EUR |
| 1651.59 Mio. EUR |
| - |
| -141.68 Mio. EUR |
| -156.57 Mio. EUR |
| -1.76 EUR |
| 34.57 Mio. EUR |
| 219.65 Mio. EUR |
| -112.31 Mio. EUR |
| 6.17 |
| - |
| -49.06% |
| - |
| - |
| - |
| DEFINIUM |
| 23.04.26 |
|